Coherus BioSciences (FRA:8C5) Dividends per Share : €0.00 (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Dividends per Share?

Coherus BioSciences's dividends per share for the three months ended in Mar. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Coherus BioSciences's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Coherus BioSciences Dividends per Share Historical Data

The historical data trend for Coherus BioSciences's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Dividends per Share Chart

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Coherus BioSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Coherus BioSciences's Dividends per Share

For the Biotechnology subindustry, Coherus BioSciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus BioSciences's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Dividend Yield % falls into.

Coherus BioSciences Dividends per Share Calculation

Dividends paid to per common share.

Coherus BioSciences (FRA:8C5) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Coherus BioSciences's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	Earnings per Share (Diluted) (Q: Mar. 2024 )
	=	0	/	0.764
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Coherus BioSciences Dividends per Share Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences (FRA:8C5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

CHRS:USA

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines